3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Hemorrhage
13
Neoplasms
7
Leiomyoma
6
Breast Neoplasms
6
Hematologic Neoplasms
4
Thrombocytopenia
3
Postoperative Hemorrhage
3
Meningioma
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Seroma
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Myofibroma
2
Head and Neck Neoplasms
2
Colonic Neoplasms
2
Brain Neoplasms
2
Bone Neoplasms
2
Blood Loss, Surgical
2
Wrist Fractures
1
Urologic Diseases
1
Urinary Retention
1
Thromboembolism
1
Skin Neoplasms
1
Seizures
1
Sarcoma
1
Recurrence
1
Postoperative Complications
1
Polyposis, Gastric
1
Pituitary Neoplasms
1
Interventions
Cyclophosphamide
209
fludarabine phosphate
184
Azacitidine
159
fludarabine
142
Busulfan
138
Tacrolimus
119
Mycophenolic Acid
111
Cytarabine
110
Whole-Body Irradiation
106
Peripheral Blood Stem Cell Transplantation
98
Antilymphocyte Serum
97
Melphalan
90
Filgrastim
87
Cyclosporine
83
Decitabine
82
Methotrexate
79
venetoclax
63
Granulocyte Colony-Stimulating Factor
56
Radiotherapy
49
Stem Cell Transplantation
48
Thiotepa
47
Cord Blood Stem Cell Transplantation
42
Clofarabine
42
thymoglobulin
41
Specimen Handling
35
Etoposide
35
Methylprednisolone
34
Sirolimus
33
Injections
27
Biopsy
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Myelodysplastic Syndromes
×
Tranexamic Acid
×
Clear all
NCT06599762
2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2
Recruiting
75 enrolled